Gadolinium and platinum in tandem: Real-time multi-modal monitoring of drug delivery by mri and fluorescence imaging

Hongguang Li; Bethany I. Harriss; Alkystis Phinikaridou; Sara Lacerda; Gregory Ramniceanu; Bich Thuy Doan; Ka Lok Ho; Chi Fai Chan; Wai Sum Lo; René M. Botnar; Rongfeng Lan; Cyrille Richard; Ga Lai Law; Nicholas J. Long; Ka Leung Wong

doi:10.7150/ntno.18619

Gadolinium and platinum in tandem: Real-time multi-modal monitoring of drug delivery by mri and fluorescence imaging

Hongguang Li
, Bethany I. Harriss
, Alkystis Phinikaridou
, Sara Lacerda
, Gregory Ramniceanu
, Bich Thuy Doan
, Ka Lok Ho
, Chi Fai Chan
, Wai Sum Lo
, René M. Botnar
, Rongfeng Lan
, Cyrille Richard
, Ga Lai Law
, Nicholas J. Long
, Ka Leung Wong

Research output: Journal article publication › Journal article › Academic research › peer-review

16 Citations (Scopus)

Abstract

A novel dual-imaging cisplatin-carrying molecular cargo capable of performing simultaneous optical and MR imaging is reported herein. This long-lasting MRI contrast agent (r₁ relaxivity of 23.4 mM^-1s^-1 at 3T, 25^o C) is a photo-activated cisplatin prodrug (PtGdL) which enables real-time monitoring of anti-cancer efficacy. PtGdL is a model for monitoring the drug delivery and anti-cancer efficacy by MRI with a much longer retention time (24 hours) in several organs such as renal cortex and spleen than GdDOTA and its motif control GdL. Upon complete release of cisplatin, all PtGdL is converted to GdL enabling subsequent MRI analyses of therapy efficacy within its reasonably short clearance time of 4 hours. There is also responsive fluorescence enhancement for monitoring by photon-excitation.

Original language	English
Pages (from-to)	186-195
Number of pages	10
Journal	Nanotheranostics
Volume	1
Issue number	2
DOIs	https://doi.org/10.7150/ntno.18619
Publication status	Published - 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cisplatin
Drug delivery
Fluorescence imaging
MRI
Multi-modal
Prodrug

ASJC Scopus subject areas

Biotechnology
Medicine (miscellaneous)
Biomedical Engineering
Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

More information

10.7150/ntno.18619

http://hdl.handle.net/10397/72216

Cite this

Li, H., Harriss, B. I., Phinikaridou, A., Lacerda, S., Ramniceanu, G., Doan, B. T., Ho, K. L., Chan, C. F., Lo, W. S., Botnar, R. M., Lan, R., Richard, C., Law, G. L., Long, N. J., & Wong, K. L. (2017). Gadolinium and platinum in tandem: Real-time multi-modal monitoring of drug delivery by mri and fluorescence imaging. Nanotheranostics, 1(2), 186-195. https://doi.org/10.7150/ntno.18619

@article{d75be9244d0d44cb8bb110739934f3f5,

title = "Gadolinium and platinum in tandem: Real-time multi-modal monitoring of drug delivery by mri and fluorescence imaging",

abstract = "A novel dual-imaging cisplatin-carrying molecular cargo capable of performing simultaneous optical and MR imaging is reported herein. This long-lasting MRI contrast agent (r1 relaxivity of 23.4 mM-1s-1 at 3T, 25o C) is a photo-activated cisplatin prodrug (PtGdL) which enables real-time monitoring of anti-cancer efficacy. PtGdL is a model for monitoring the drug delivery and anti-cancer efficacy by MRI with a much longer retention time (24 hours) in several organs such as renal cortex and spleen than GdDOTA and its motif control GdL. Upon complete release of cisplatin, all PtGdL is converted to GdL enabling subsequent MRI analyses of therapy efficacy within its reasonably short clearance time of 4 hours. There is also responsive fluorescence enhancement for monitoring by photon-excitation.",

keywords = "Cisplatin, Drug delivery, Fluorescence imaging, MRI, Multi-modal, Prodrug",

author = "Hongguang Li and Harriss, \{Bethany I.\} and Alkystis Phinikaridou and Sara Lacerda and Gregory Ramniceanu and Doan, \{Bich Thuy\} and Ho, \{Ka Lok\} and Chan, \{Chi Fai\} and Lo, \{Wai Sum\} and Botnar, \{Ren{\'e} M.\} and Rongfeng Lan and Cyrille Richard and Law, \{Ga Lai\} and Long, \{Nicholas J.\} and Wong, \{Ka Leung\}",

note = "Funding Information: This work is funded by the Hong Kong Baptist University (FRG2/15-16/009), PNCORE (F-HKBU203/14), Hong Kong Polytechnic University (HKPolyU), Hong Kong Research Grants Council (HKBU 12309516), Hong Kong Polytechnic University central Research Grant (G-UC08), HKBU-HKPolyU Joint Research Programme (RC-ICRS/15-16/02F-WKL02F-WKL) and a Royal Society International Exchange grant, Institut Weizmann Fran?ais Grant, CNRS, IDEX Programme interdisciplinaire, Universit? Paris Descartes and PHC PROCORE (project 33122PA). Funding Information: This work is funded by the Hong Kong Baptist University (FRG2/15-16/009), PNCORE (F-HKBU203/14), Hong Kong Polytechnic University (HKPolyU), Hong Kong Research Grants Council (HKBU 12309516), Hong Kong Polytechnic University central Research Grant (G-UC08), HKBU-HKPolyU Joint Research Programme (RC-ICRS/15-16/02F-WKL02F-WKL) and a Royal Society International Exchange grant, Institut Weizmann Fran{\c c}ais Grant, CNRS, IDEX Programme interdisciplinaire, Universit{\'e} Paris Descartes and PHC PROCORE (project 33122PA). Publisher Copyright: {\textcopyright} Ivyspring International Publisher.",

year = "2017",

doi = "10.7150/ntno.18619",

language = "English",

volume = "1",

pages = "186--195",

journal = "Nanotheranostics",

issn = "2206-7418",

publisher = "Ivyspring International Publisher",

number = "2",

}

TY - JOUR

T1 - Gadolinium and platinum in tandem: Real-time multi-modal monitoring of drug delivery by mri and fluorescence imaging

AU - Li, Hongguang

AU - Harriss, Bethany I.

AU - Phinikaridou, Alkystis

AU - Lacerda, Sara

AU - Ramniceanu, Gregory

AU - Doan, Bich Thuy

AU - Ho, Ka Lok

AU - Chan, Chi Fai

AU - Lo, Wai Sum

AU - Botnar, René M.

AU - Lan, Rongfeng

AU - Richard, Cyrille

AU - Law, Ga Lai

AU - Long, Nicholas J.

AU - Wong, Ka Leung

N1 - Funding Information: This work is funded by the Hong Kong Baptist University (FRG2/15-16/009), PNCORE (F-HKBU203/14), Hong Kong Polytechnic University (HKPolyU), Hong Kong Research Grants Council (HKBU 12309516), Hong Kong Polytechnic University central Research Grant (G-UC08), HKBU-HKPolyU Joint Research Programme (RC-ICRS/15-16/02F-WKL02F-WKL) and a Royal Society International Exchange grant, Institut Weizmann Fran?ais Grant, CNRS, IDEX Programme interdisciplinaire, Universit? Paris Descartes and PHC PROCORE (project 33122PA). Funding Information: This work is funded by the Hong Kong Baptist University (FRG2/15-16/009), PNCORE (F-HKBU203/14), Hong Kong Polytechnic University (HKPolyU), Hong Kong Research Grants Council (HKBU 12309516), Hong Kong Polytechnic University central Research Grant (G-UC08), HKBU-HKPolyU Joint Research Programme (RC-ICRS/15-16/02F-WKL02F-WKL) and a Royal Society International Exchange grant, Institut Weizmann Français Grant, CNRS, IDEX Programme interdisciplinaire, Université Paris Descartes and PHC PROCORE (project 33122PA). Publisher Copyright: © Ivyspring International Publisher.

PY - 2017

Y1 - 2017

N2 - A novel dual-imaging cisplatin-carrying molecular cargo capable of performing simultaneous optical and MR imaging is reported herein. This long-lasting MRI contrast agent (r1 relaxivity of 23.4 mM-1s-1 at 3T, 25o C) is a photo-activated cisplatin prodrug (PtGdL) which enables real-time monitoring of anti-cancer efficacy. PtGdL is a model for monitoring the drug delivery and anti-cancer efficacy by MRI with a much longer retention time (24 hours) in several organs such as renal cortex and spleen than GdDOTA and its motif control GdL. Upon complete release of cisplatin, all PtGdL is converted to GdL enabling subsequent MRI analyses of therapy efficacy within its reasonably short clearance time of 4 hours. There is also responsive fluorescence enhancement for monitoring by photon-excitation.

AB - A novel dual-imaging cisplatin-carrying molecular cargo capable of performing simultaneous optical and MR imaging is reported herein. This long-lasting MRI contrast agent (r1 relaxivity of 23.4 mM-1s-1 at 3T, 25o C) is a photo-activated cisplatin prodrug (PtGdL) which enables real-time monitoring of anti-cancer efficacy. PtGdL is a model for monitoring the drug delivery and anti-cancer efficacy by MRI with a much longer retention time (24 hours) in several organs such as renal cortex and spleen than GdDOTA and its motif control GdL. Upon complete release of cisplatin, all PtGdL is converted to GdL enabling subsequent MRI analyses of therapy efficacy within its reasonably short clearance time of 4 hours. There is also responsive fluorescence enhancement for monitoring by photon-excitation.

KW - Cisplatin

KW - Drug delivery

KW - Fluorescence imaging

KW - MRI

KW - Multi-modal

KW - Prodrug

UR - https://www.scopus.com/pages/publications/85044039193

U2 - 10.7150/ntno.18619

DO - 10.7150/ntno.18619

M3 - Journal article

C2 - 29071187

AN - SCOPUS:85044039193

SN - 2206-7418

VL - 1

SP - 186

EP - 195

JO - Nanotheranostics

JF - Nanotheranostics

IS - 2

ER -

Gadolinium and platinum in tandem: Real-time multi-modal monitoring of drug delivery by mri and fluorescence imaging

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

More information

Other files and links

Fingerprint

Cite this